{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:16Z","timestamp":1793815576249,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01 CA176067-01A1"],"award-info":[{"award-number":["U01 CA176067-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA-16359"],"award-info":[{"award-number":["CA-16359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deborah Bunn Alley Foundation"},{"name":"Tina Brozman Foundation"},{"DOI":"10.13039\/100012175","name":"Discovery to Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012175","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guido Berlucchi Foundation"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"SU2C","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ygyno.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T19:13:44Z","timestamp":1546974824000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["PI3K oncogenic mutations mediate resistance to afatinib in HER2\/neu overexpressing gynecological cancers"],"prefix":"10.1016","volume":"153","author":[{"given":"Elena","family":"Bonazzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zammataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-2493","authenticated-orcid":false,"given":"Emanuele","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Espinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulden","family":"Menderes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Altwerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanhee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Zeybek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Litkouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Arin","family":"Silasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.01.002_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0010","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0015","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0030","article-title":"Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0035","first-page":"165","article-title":"The biology of erbB-2\/neu\/HER-2 and its role in cancer","volume":"1198","author":"Hynes","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0040","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrclinonc.2011.45","article-title":"Targeting the human EGFR family in esophagogastric cancer","volume":"8","author":"Okines","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0045","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0055","first-page":"14","article-title":"HER-2\/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization","volume":"18","author":"Odicino","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0060","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng.2455","article-title":"Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes","volume":"44","author":"Le Gallo","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001138","article-title":"HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients","volume":"2","author":"Tuefferd","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0075","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2018.03.014","article-title":"A comprehensive pan-cancer molecular study of gynecologic and breast cancers","volume":"33","author":"Berger","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0080","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1078-0432.CCR-10-0540","article-title":"A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas","volume":"17","author":"Rudd","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0085","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1073\/pnas.1704706114","article-title":"PI3K-p110alpha mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85alpha","volume":"114","author":"Thorpe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0090","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0095","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0100","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0105","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2015.306","article-title":"PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2\/neu overexpressing uterine serous carcinomas","volume":"113","author":"Black","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0110","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/1078-0432.CCR-18-0864","article-title":"Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer","volume":"24","author":"Bonazzoli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molcel.2015.12.013","article-title":"HELB is a feedback inhibitor of DNA end resection","volume":"61","author":"Tkac","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-013-0024-9","article-title":"HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies","volume":"17","author":"English","year":"2013","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2010.01.043","volume":"118","author":"Santin","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0145","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O'Brien","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0150","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/bjc.2011.369","article-title":"Her2\/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab","volume":"105","author":"Todeschini","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0155","first-page":"2247","article-title":"A truncated intracellular HER2\/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells","volume":"13","author":"Scott","year":"1993","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0160","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1038\/sj.emboj.7601191","article-title":"Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation","volume":"25","author":"Anido","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0165","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0170","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","article-title":"A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab","volume":"133","author":"Lin","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","article-title":"Acquired resistance to drugs targeting tyrosine kinases","volume":"138","author":"Rosenzweig","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0180","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ctrv.2013.10.002","article-title":"Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)","volume":"40","author":"Cohen","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0185","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-15-0383","article-title":"Dual HER2\/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo","volume":"14","author":"Lopez","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0190","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/bjc.2014.519","article-title":"Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo","volume":"111","author":"Schwab","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2019.01.002_bb0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12032-017-0956-8","article-title":"Efficacy of neratinib in the treatment of HER2\/neu-amplified epithelial ovarian carcinoma in vitro and in vivo","volume":"34","author":"Menderes","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ygyno.2019.01.002_bb0200","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2014.08.024","article-title":"Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2\/neu amplified uterine serous carcinoma in vitro and in vivo","volume":"135","author":"Lopez","year":"2014","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819300046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819300046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:41:06Z","timestamp":1758771666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819300046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0090825819300046"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K oncogenic mutations mediate resistance to afatinib in HER2\/neu overexpressing gynecological cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}